Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05604131 · ClinicalTrials.gov registry record · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
A Phase 2 study of Acute Myocardial Infarction Type 1, sponsored by Rohan Dharmakumar.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
- 1
- Study location
NCT05604131: Recruiting Phase 2 study of Acute Myocardial Infarction Type 1, sponsored by Rohan Dharmakumar.
NCT05604131 is a Phase 2 study of Acute Myocardial Infarction Type 1 that is actively recruiting participants, run by Rohan Dharmakumar. The registered enrollment target is 89 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05604131, a Phase 2 study of Acute Myocardial Infarction Type 1, is actively recruiting participants, sponsored by Rohan Dharmakumar.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this randomized, controlled pilot study is to determine the efficacy of Deferiprone to reduce the amount of free iron inside the hemorrhagic zone of myocardial infarction among hemorrhagic myocardial infarction patients.
Primary Outcome
Percentage reduction of hemorrhagic zone iron content by cardiac magnetic resonance at 6 months relative to baseline
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Deferiprone Tablets
Study Locations (1)
Indiana
- IU Methodist Hospital (IUHealth) - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2022-11-08 |
| Est. Completion | 2029-08-31 |
| Phase | Phase 2 |
What NCT05604131 shows while recruiting
NCT05604131 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (33% lower).
The record links to 1 condition, with Acute Myocardial Infarction Type 1 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05604131 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT05604131 about?
NCT05604131 is a clinical study titled "Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients". The objective of this randomized, controlled pilot study is to determine the efficacy of Deferiprone to reduce the amount of free iron inside the hemorrhagic zone of myocardial infarction among hemorrhagic myocardial infarction patients.
What is the current status of trial NCT05604131?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2022-11-08. Estimated completion is 2029-08-31.
What conditions does trial NCT05604131 study?
This clinical trial studies the following conditions: Acute Myocardial Infarction Type 1.
What interventions are being tested in trial NCT05604131?
The interventions under investigation include: Placebo (DRUG), Deferiprone Tablets (DRUG).
Who is sponsoring clinical trial NCT05604131?
This trial is sponsored by Rohan Dharmakumar, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05604131 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05604131's enrollment target sits among peer trials
89 802nd of 2000 higher than 1,198 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT07015983 · 89 participants · Phase 2
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI